Spoken Alpha
TriSalus Life Sciences, Inc.
TriSalus Life Sciences designs and manufactures medical devices and develops immunotherapies for treating solid tumors. The company's lead product, TriNav, is an FDA-cleared catheter system using Pressure-Enabled Drug Delivery (PEDD) technology to improve therapeutic delivery to liver tumors during procedures like radioembolization and chemoembolization.
TriSalus Life Sciences, Inc is a Healthcare company operating in Medical Devices with a $293.7M market cap.
TLSI missed consensus EPS by 0.1% in Q2 FY2026, reported Aug 5, 2026.
12 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TLSI.
$ curl https://api.spokenalpha.com/v1/companies/TLSIFAQ
Spoken Alpha indexes TLSI's earnings call transcripts at https://spokenalpha.com/companies/TLSI. Each call links to attributed speakers and parsed analyst Q&A. TriSalus Life Sciences, Inc.'s own investor relations page is at https://trisaluslifesciences.com/investors.
TriSalus Life Sciences, Inc. (TLSI) held its most recent earnings call on 2026-08-06, covering fiscal Q2 2026.
TriSalus Life Sciences, Inc. (TLSI) operates in the Healthcare sector (Medical Devices industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | $-0.16 | $-0.15 | -6.7% | $11.4M | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $0.03 | $-0.16 | +100.0% | $8.9M | — | — | EODHD |
| Q4 FY2025 | 2026-03-04 | $-0.05 | $-0.13 | +61.5% | $13.2M | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.87 | $-0.16 | -100.0% | $11.6M | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.23 | $-0.22 | -4.5% | $11.2M | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.33 | $-0.20 | -65.0% | $9.2M | — | — | EODHD |
| Q4 FY2024 | 2025-03-26 | $-0.40 | $-0.35 | -14.3% | $8.3M | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-0.40 | $-0.36 | -11.1% | $7.3M | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.21 | $-0.46 | +54.4% | $7.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-0.60 | $-0.72 | +16.7% | $6.5M | — | — | EODHD |
| Q4 FY2023 | 2023-12-30 | $-1.56 | $-0.69 | -100.0% | $5.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.13 | — | — | $5.2M | — | — | EODHD |
| Q2 FY2023 | 2023-08-29 | $-0.12 | — | — | $4.6M | — | — | EODHD |
| Q1 FY2023 | 2023-03-30 | $-0.05 | — | — | $3.0M | — | — | EODHD |
| Q4 FY2022 | 2023-03-21 | $-0.01 | $0.00 | — | $3.2M | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $0.02 | $0.00 | — | $3.9M | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $0.08 | $0.00 | — | $2.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $0.09 | $0.00 | — | $2.4M | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $0.09 | $0.00 | — | $2.6M | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $0.06 | $0.00 | — | — | — | — | EODHD |
Source: EODHD. TLSI reported actuals as published; sparse fields render as —.